424 related articles for article (PubMed ID: 16960863)
1. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
2. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
Cummings J; Emre M; Aarsland D; Tekin S; Dronamraju N; Lane R
J Alzheimers Dis; 2010; 20(1):301-11. PubMed ID: 20164585
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
5. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
7. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
Olin JT; Aarsland D; Meng X
Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050
[TBL] [Abstract][Full Text] [Related]
10. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML
Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447
[TBL] [Abstract][Full Text] [Related]
11. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
13. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine in Parkinson's disease dementia.
Lalli S; Albanese A
Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
[TBL] [Abstract][Full Text] [Related]
15. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine in Parkinson's disease dementia.
Chitnis S; Rao J
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
[TBL] [Abstract][Full Text] [Related]
18. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
Cummings J; Winblad B
Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
20. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
